Natera to Seek FDA Clearance of Oncology Assay as NIPT Business Continues to Grow - 360Dx

Natera to Seek FDA Clearance of Oncology Assay as NIPT Business Continues to Grow 360Dx Rabinowitz said that the firm plans to leverage its existing phlebotomist infrastructure that it has in place for its NIPT business when it launches the clinical version of Signatera. It will also take a similar commercialization strategy that it took ...

from phlebotomist - Google News http://bit.ly/2KRt9do